Redmile Group, LLC Fate Therapeutics Inc Transaction History

Redmile Group, LLC

$1.53 Billion
Q2 2024

A detailed history of Redmile Group, LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Redmile Group, LLC holds 13,169,057 shares of FATE stock, worth $44.6 Million. This represents 2.82% of its overall portfolio holdings.

Number of Shares

13,169,057

Previous 13,169,057 -0.0%

Holding current value

$44.6 Million

Previous $96.7 Million 55.31%

% of portfolio

2.82%

Previous 3.81%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $73,639 - $175,842	44,630 Added 0.34%	13,169,057 $49.3 Million
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $795,895 - $1.1 Million	167,205 Added 1.29%	13,124,427 $62.5 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $23.6 Million - $38.4 Million	327,485 Added 2.59%	12,957,222 $1.07 Billion
Q2 2020 Aug 14, 2020	BUY	$20.21 - $35.23 $28.6 Million - $49.8 Million	1,412,928 Added 12.6%	12,629,737 $433 Million
Q3 2019 Nov 14, 2019	BUY	$15.47 - $22.5 $13.3 Million - $19.3 Million	857,143 Added 8.27%	11,216,809 $174 Million
Q4 2018 May 16, 2019	SELL	$11.48 - $16.98 $2.49 Million - $3.68 Million	-216,697 Reduced 2.05%	10,359,666 $133 Million
Q4 2018 Feb 14, 2019	BUY	$11.48 - $16.98 $2.49 Million - $3.68 Million	216,697 Added 2.09%	10,576,363 $136 Million
Q3 2018 May 16, 2019	SELL	$8.75 - $16.29 $1.9 Million - $3.53 Million	-216,697 Reduced 2.05%	10,359,666 $169 Million
Q3 2018 Nov 14, 2018	BUY	$8.75 - $16.29 $34.3 Million - $63.9 Million	3,920,401 Added 58.9%	10,576,363 $172 Million
Q1 2018 May 15, 2018	BUY	$6.3 - $13.77 $7.5 Million - $16.4 Million	1,190,476 Added 21.78%	6,655,962 $0
Q4 2017 Feb 14, 2018	BUY	$3.94 - $6.64 $15.9 Million - $26.9 Million	4,046,428 Added 285.15%	5,465,486 $33.4 Million
Q3 2017 Nov 14, 2017	BUY	$2.6 - $4.31 $3.69 Million - $6.12 Million	1,419,058	1,419,058 $5.62 Million

Others Institutions Holding FATE

# of Institutions

190

Shares Held

123M

Call Options Held

15K

Put Options Held

14K

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $329M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Redmile Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Redmile Group, LLC with notifications on news.

Account

Redmile Group, LLC Fate Therapeutics Inc Transaction History